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Axon loss contributes to many common neurodegenerative disorders. In healthy axons, the axon survival factor
NMNAT2 inhibits SARM1, the central executioner of programmed axon degeneration. We identified 2 rare NMNAT2
missense variants in 2 brothers afflicted with a progressive neuropathy syndrome. The polymorphisms resulted in
amino acid substitutions V98M and R232Q, which reduced NMNAT2 NAD+-synthetase activity. We generated a mouse
model to mirror the human syndrome and found that Nmnat2V98M/R232Q compound-heterozygous CRISPR mice survived
to adulthood but developed progressive motor dysfunction, peripheral axon loss, and macrophage infiltration. These
disease phenotypes were all SARM1-dependent. Remarkably, macrophage depletion therapy blocked and reversed
neuropathic phenotypes in Nmnat2V98M/R232Q mice, identifying a SARM1-dependent neuroimmune mechanism as a
key driver of disease pathogenesis. These findings demonstrate that SARM1 induced inflammatory neuropathy and
highlight the potential of immune therapy as a treatment for this rare syndrome and other neurodegenerative conditions
associated with NMNAT2 loss and SARM1 activation.

Introduction

Axon loss is one of the earliest pathological hallmarks — and
likely the initiating event — in many common neurodegenerative disorders (1–3). Programmed axon degeneration is an active,
genetically encoded, subcellular, self-destruction pathway executed by the prodegenerative NADase enzyme sterile α and
Toll/interleukin-1 receptor motif-containing (SARM1) (4, 5). In a
healthy axon, SARM1 activity is restrained by the NAD+ biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), which converts NMN and ATP into NAD+ (6).
NMNAT2 is a highly labile protein produced in the soma and trafficked into the axon (7). Nerve injury blocks axonal transport and
leads to rapid depletion of axonal NMNAT2 (8), causing NMN
buildup and NAD+ loss. Recent breakthroughs led to the discovery that SARM1 is activated by an increase in the ratio of NMN to
NAD+ (9). NMN and NAD+ can both bind at an allosteric site in
the enzyme’s N-terminus to differentially regulate its conformation, and hence, the activation state of SARM1 (9–12). The ratio
of NMN/NAD+ rises after NMNAT2 loss, favoring SARM1 activation and subsequent axon degeneration (9). Genetic deletion of
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NMNAT2 alone is perinatal lethal; however, when combined with
SARM1 deletion, mice are viable and resistant to injury-induced
axon degeneration, suggesting that an essential role of NMNAT2
is the inhibition of SARM1 (13).
SARM1 is the central executioner of a cell-autonomous
axon-degeneration program. Upon activation, SARM1, an NAD+
hydrolase, depletes axonal NAD+ levels, culminating in metabolic
crisis and axon fragmentation. Acute injury is the best-understood
trigger of pathological axon degeneration, inducing distal axon
loss (5, 14–19). Loss of SARM1 is protective in models of chemotherapy-induced peripheral neuropathy (CIPN) (15, 17) and traumatic brain injury (TBI) (16). However, programmed axon degeneration is also common in chronic neurodegenerative disease
models that do not include acute axonal injury (3), suggesting a
role for subacute SARM1 activation in the pathogenesis of a wide
range of chronic neurodegenerative conditions.
Evidence for the involvement of the NMNAT2/SARM1 axon
degeneration pathway in chronic disease has emerged from studying
rare human mutations in patients. Indeed, in a model of Leber congenital amaurosis type 9, SARM1 depletion rescues photoreceptor
cell death caused by loss of the nuclear NMNAT isoform, NMNAT1
(20). Furthermore, NMNAT2 mutations were identified in a still-born
fetus with fetal akinesia deformation sequence and in 2 sisters suffering from a mild polyneuropathy (21, 22). The first direct evidence of
SARM1 mutations in human disease emerged with the discovery of
rare hypermorphic SARM1 alleles in a subset of patients with ALS (23,
24). However, we believe that until the present study, the field lacked
a mechanistically defined disease model of a SARM1-dependent,
chronic axonopathy (Herein referred to as SARMopathy).
1
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Here we examine 2 brothers that presented in early childhood
with recurring Guillain-Barré–like episodes requiring mechanical
ventilation combined with severe, progressive peripheral neurodegeneration. Whole exome sequencing revealed that they are
both compound heterozygotes for 2 rare missense variants in the
NMNAT2 gene, each inherited from 1 of their parents. We created a mouse that harbors both mutant NMNAT2 alleles and found
that this model recapitulates key features of the human syndrome.
NMNAT2 is the endogenous inhibitor of SARM1 in axons; thus,
defects in NMNAT2 can trigger aberrant activation of SARM1.
Indeed, we find that these disease phenotypes are all SARM1-dependent. While SARM1 is best understood as the executioner of a
cell-autonomous, axo-destructive program, here we make the surprising discovery that SARM1 also promotes axon degeneration via
induction of non-cell-autonomous macrophage activation.
Macrophages play complex roles as both prodegenerative
and prorestorative immune cells. Indeed, neuroinflammation
has been referred to as a double-edged sword as it can have both
beneficial and deleterious effects on the nervous system (25). On
one hand, in the peripheral nervous system, macrophages play
a necessary role in facilitating axon regeneration through the
clearance of myelin and axonal debris after nerve injury (26–28).
Indeed, macrophage depletion hampers axon regeneration after
peripheral nerve injury (29–32). However, macrophages and their
CNS counterparts, microglia, are also drivers of disease in several
common neurodegenerative diseases, including multiple sclerosis
(MS) (33), CIPN (34), and Alzheimer’s disease (AD) (35). In these
disease models, depletion of macrophages and microglia can mitigate disease phenotypes, suggesting a conserved prodegenerative
role for phagocytes in human neurological disease.
Collectively, our data establish NMNAT2 variants as the genetic
basis of a human neuropathy and demonstrate an unexpected role for
SARM1 as a driver of neuroinflammation in the peripheral nervous
system. In this model, we demonstrate that AAV-mediated delivery of a SARM1 dominant negative (SARM1-DN) gene therapeutic
inhibited the development of motor neuropathy. In addition, we
found that macrophage depletion early in the disease course could
block the development of neuropathy and that, remarkably, treatment after symptom onset could reverse neuropathic phenotypes.
Our study provides what we believe to be the first mouse model of
a chronic, injury-independent SARMopathy with which to test axon
degeneration-blocking treatments. This will be of substantial benefit and high clinical relevance as the field uncovers an ever-growing list of chronic neurodegenerative diseases that involve SARM1
activation. Importantly, our work uncovered a SARM1-dependent
non-cell-autonomous mechanism of axon loss and highlights macrophage depletion as a potent axoprotective therapeutic strategy.

Results

Rare missense variants in NMNAT2 cause hereditary neuropathy.
Patients 1 and 2 are brothers from nonconsanguineous, healthy
parents of African American ancestry. No other members of the
extended family are known to be affected. Patient 1 was born following an uneventful pregnancy. Development was normal and
the patient acquired the ability to walk before the onset of illness.
At age 13 months, he experienced an acute episode of hypotonia,
weakness, and respiratory failure that required hospitalization
2

and mechanical ventilation. Electrophysiology testing (nerve conduction studies and electromyography) at the time of symptom
onset showed features of multifocal, sensory, and motor neuropathy thought to be consistent with Guillain-Barré syndrome. After
treatment with intravenous immune globulin and steroids, he
regained some motor function and was taken off ventilatory support but exhibited residual weakness.
In subsequent years he developed a unique sensorimotor syndrome comprising both chronic and episodic features. Episodic
attacks are frequently contemporaneous with infection and include
severe neuropathic pain, worsening erythromelalgia, flaccid quadriparesis, and respiratory failure requiring mechanical ventilation. During these episodes, electrophysiological testing showed
a complete absence of sensory and motor responses. In between
episodes, the patient experienced a chronic, progressive motor-predominant peripheral neuropathy. Currently 25-years-old, patient 1
is cognitively normal and attends college. Electrophysiology testing
indicated a predominantly motor axonal neuropathy. He is wheelchair-dependent, exhibits progressive scoliosis, poor weight gain,
and has severe combined proximal and distal muscle atrophy with
predominantly distal muscle weakness. Muscle ultrasound revealed
fatty, fibrotic tissue replacement of muscle, consistent with chronic
neuropathy (36). The patient also experiences recurring neuropathic pain, erythromelalgia, bilateral optic atrophy, and tongue fasciculation. Cranial and spinal MRI are normal except for mildly prominent extra-axial spaces. At age 15, a head CT showed mild diffuse
parenchymal atrophy or pseudoatrophy.
Patient 2 was born 3 years after patient 1 following an uneventful pregnancy. His first episode of severe weakness requiring
mechanical ventilation occurred at 11 months. Patient 2’s clinical
course has been virtually identical to his brother’s with very similar symptoms and degree of impairment.
Whole-exome sequencing was performed on the brothers and
their parents to identify candidate variants that may have caused
the patients’ disease. Both affected patients share rare, compound
heterozygous variants (c. 695G>A [p.Arg232Gln] and c.292G>A
[p.Val98Met]; R232Q and V98M, respectively) in NMNAT2. Each
parent was found to be heterozygous for 1 of the 2 variants identified in the patients (Figure 1A). R232Q was previously identified as
a loss-of-function variant associated with fetal akinesia deformation sequence and occurs in a region of NMNAT2 involved in substrate binding (22). V98M appeared to be a novel NMNAT2 variant
of unknown significance. Both variants occurred at residues that
are conserved in all 3 human NMNAT isoforms (Figure 1, B and C).
V98M reduces NMNAT2 NAD+ synthetase activity but not protein
stability. We sought to elucidate the functional consequences of
the NMNAT2 variant alleles. To investigate whether NMNAT2V98M
altered protein stability, we used immunoblotting to compare its relative half life to NMNAT2R232Q and NMNAT2WT in transfected HEK
cells. In line with prior studies of NMNAT2 half life (8), protein synthesis blockade led to a rapid drop in NMNAT2 protein levels. Turnover rates of NMNAT2V98M and NMNAT2R232Q were not significantly
different from that of control NMNAT2 (Figure 1D).
NMNAT2 is an NAD+ synthesizing enzyme, and this activity
is required for its function as an axon survival factor. To investigate whether NMNAT2V98M has impaired enzymatic activity, we
purified recombinant Strep-tagged NMNAT2 proteins using affin-
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Figure 1. Identification of compound heterozygous NMNAT2 variants in 2 brothers with relapsing-remitting neuropathy. (A) Both brothers carry 2
extremely rare missense mutations in the NMNAT2 gene (c.292G>A. c.695G>A), each inherited from 1 of their parents. Half-shaded represents heterozygous, unaffected. Fully-shaded represents compound heterozygous, affected. (B) V98 and R232 residues are conserved in all 3 human NMNAT isoforms.
(C) Schematic of NMNAT structure. Patients’ missense variants noted in red (V98) and blue (R232). W169 (green) is the catalytic residue. (D) Relative
turnover rates for Flag-NMNAT2 (WT, V98M, R232Q) after cycloheximide (CHX) addition. 1-phase decay curves were fitted to the data using nonlinear
regression. (E) NMNAT activity assay. NAD+ production at steady state (10 minutes) was used to calculate the NMNAT activity. All data are presented as
mean ± SEM from n = 5 independent experiments. Statistical significance determined by 2-way ANOVA with multiple comparisons. ****P < 0.0001.

ity chromatography (37). In agreement with previous findings
(22), NMNAT2V98M had 14.6% of the NAD+ synthesis activity of
NMNAT2WT at 37°C, whereas NMNAT2R232Q was 4.4% as active
as the NMNAT2WT enzyme (Figure 1E). Collectively, these data
demonstrate that these NMNAT2 variants disrupt enzymatic function, which may underly their pathogenicity.
Nmnat2V98M/R232Q mice develop progressive motor neuropathy. To
study the pathological effects of the V98M and R232Q NMNAT2
mutations found in these patients, we used CRISPR-induced
mutagenesis to create mice with the Nmnat2V98M or Nmnat2R232Q
mutations (see Methods). Mice heterozygous for these individual mutations were mated to generate mice with compound heterozygous Nmnat2V98M and Nmnat2R232Q mutations (henceforth
referred to as Nmnat2V98M/R232Q mice). These mice were viable with
no evidence of embryonic or perinatal lethality. As patients with
compound heterozygous variants in NMNAT2 exhibit a chronic,
motor-predominant peripheral neuropathy, we searched for similar phenotypes in the Nmnat2V98M/R232Q mice. Starting at 2 months,
we assayed muscle strength using an inverted screen test and
found that the mice exhibited age-dependent, progressive muscle weakness (Figure 2A). The human disorder involves predominantly distal muscle atrophy; therefore, we assayed hindlimb
grip strength in the Nmnat2V98M/R232Q mice. We observed a decline
in distal muscle strength (Figure 2B). Gait defects manifested
in Nmnat2V98M/R232Q mice as young as 6 months old, concomitant
with progressive lower limb muscular atrophy. The majority of

mice displayed severe hindlimb wasting and difficulty walking by
9–12 months of age (Supplemental Video 1; supplemental material available online with this article; https://doi.org/10.1172/
JCI159800DS1). Notably, while patients have episodic neuropathic pain, we did not elicit a nociceptive defect in tail flick testing of
Nmnat2V98M/R232Q mice (Figure 2C).
Nmnat2V98M/R232Q mice have electrophysiologic features consistent with a motor neuropathy. The decreased muscle strength
observed in Nmnat2V98M/R232Q mice suggested motor neuron dysfunction. We measured motor fiber function using compound
muscle action potential (CMAP) amplitudes and found significant deficits in Nmnat2V98M/R232Q mice. The abnormalities worsened with age, suggesting that motor axon numbers progressively diminished in parallel with decreasing overall strength (Figure
2, D and E). Next, we tested motor nerve conduction velocity
(NCV). A decrease in NCV early in disease without altered CMAP
amplitudes was indicative of demyelination, whereas a progressive drop in NCV concomitant with low CMAP amplitudes indicated large-diameter axon loss. The NCV in young Nmnat2V98M/R232Q
mice was normal, indicating that the disease is primarily an axonal neuropathy; however, NCV did decrease with age, likely due
to the eventual loss of large diameter axons (Figure 2F). Electrophysiologic sensory testing demonstrated that large, myelinated
sensory axons were not affected in Nmnat2V98M/R232Q mice (Figure
2, G and H). Pain is transmitted by small and thinly myelinated
fibers; thus, nerve conduction studies are typically unaffected
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Figure 2. Nmnat2V98M/R232Q mice have behavioral and electrophysiologic features consistent with a motor neuropathy. (A) Average time suspended from
an inverted screen (max. 120 seconds) for WT (n = 3–7) or Nmnat2V98M/R232Q (n = 3–21) mice. (B) Hindlimb grip strength for WT (n = 5–6) or Nmnat2V98M/R232Q
(n = 8–15) male mice at 2, 6, and 9–12 months. (C) Average time it takes for WT (n = 12–17) or Nmnat2V98M/R232Q (n = 13–15) mice to remove their tails from a
55°C hot water bath at 2, 6, and 9–12 months. (D and E) CMAP amplitude of WT (n = 7–13) and Nmnat2V98M/R232Q (n = 5–25) mice at the ankle (D) and sciatic
notch (E) at 2, 6, and 9–12 months. (F) NCV (m/s) of sciatic nerves of WT (n = 4–10) or Nmnat2V98M/R232Q (n = 5–25) mice at 2, 6, and 9–12 months (G) SNAP
CV (m/s) of sciatic nerves of WT (n = 6–11) or Nmnat2V98M/R232Q (n = 4–24) mice at 2, 6, and 9–12 months. (H) SNAP amplitude (μV) of sciatic nerves of WT (n
= 6–11) and Nmnat2V98M/R232Q (n = 4–24) mice at 2, 6, and 9–12 months. All data are presented as mean ± SEM. Statistical significance determined by 2-way
ANOVA with multiple comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001.

(38). Rather, intraepidermal nerve fiber density (IENFD) analysis is a more sensitive measure of small fiber loss. In agreement
with normal nociceptive function, we found that IENFD was
unaffected in Nmnat2V98M/R232Q mice (Supplemental Figure 1).
Altogether, these data demonstrate that Nmnat2V98M/R232Q mice
had a motor axonal neuropathy, consistent with the chronic
electrophysiological features of human patients with NMNAT2-
associated neuropathy.
Nmnat2 variants cause progressive axon loss and muscle wasting in
mice. To further characterize the disease process in Nmnat2V98M/R232Q
mice, we used light microscopic analysis to examine the pathology of
select peripheral nerves including the sciatic (a mixed nerve), femoral
(primarily motor), and sural (primarily sensory) in 2-month, 6-month,
and 9–12-month old mice. The sciatic and femoral nerves exhibited
severe, progressive axon loss. In contrast, we did not observe progressive axon loss in the sural nerve; however, total axon area was
4

modestly different from NmnatWT control mice at 9–12 months of age
(Figure 3, A–C). Myelin thickness was not affected in any of the nerves
we examined (Supplemental Figure 2).
We next performed electron microscopic analysis on the sciatic nerves of 2-month and 12-month-old Nmnat2V98M/R232Q mice.
The appearance of the sciatic nerve at 2 months was normal and
showed a dense population of large and small myelinated axons
with little intervening extracellular space (Figure 3D). Schwann
cells (SCs) and macrophages containing axonal and myelin debris
were found in the endoneurial space (Figure 3E, arrow). The sciatic nerve at 12 months showed patches of marked axon loss with
increased collagen and wispy processes of SCs (Figure 3F, arrow).
Following axon degeneration, perineurial cells take up lipid droplets from myelin breakdown (39); indeed, we found large perineurial droplets of neutral fat in the 12-month sciatic nerve (Figure
3G, arrow). To confirm that the observed peripheral defects were
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Figure 3. Nmnat2 variants cause progressive axon loss in mice. (A–C) Representative images of sciatic (A), femoral (B), and sural (C) nerves in 9–12-monthold Nmnat2V98M/R232Q (n = 9) or WT (n = 5) mice. Percent axonal area/total nerve area are indicated to the right (n = 4–11 mice per age cohort, per genotype).
Scale bars: 50 μm. (D) Nmnat2V98M/R232Q sciatic nerve (2 months): dense population of large and small myelinated axons with little intervening extracellular
space. (E) Nmnat2V98M/R232Q sciatic nerve (2 months): macrophage containing axonal and myelin debris in the endoneurial. (F) Nmnat2V98M/R232Q sciatic nerve (12
months): patches of marked axon loss with increased collagen and wispy processes of SC. Scattered macrophages with axonal and myelin debris were identified. (G) Nmnat2V98M/R232Q sciatic nerve (12 months): presence of large perineurial droplets of neutral fat. (H) Representative images of ChAT immunostaining in
12-month-old Nmnat2V98M/R232Q (n = 4) or WT (n = 3) spinal cord (ventral horn), scale bars: 50 μm. Quantification of number of ChAT+ motor neuron cell bodies in
the ventral horn to the right. All data are presented as mean ± SEM. Statistical significance determined by Student’s unpaired, 2-tailed t test or 2-way ANOVA
with multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

not due to motor neuron cell death, we immunostained the spinal cords of 12-month-old Nmnat2WT and Nmnat2V98M/R232Q mice
for the motor neuron marker choline acetyltransferase (ChAT)
(Figure 3H). Motor neuron cell numbers in the ventral horn were
equivalent between genotypes, and thus, axon loss in the nerves
of Nmnat2V98M/R232Q mice was likely not due to motor neuron cell
death. Taken together, these pathological features demonstrate a
progressive peripheral axonal neuropathy.
We next examined the neuromuscular junctions in the hind
paw lumbrical muscles of Nmnat2V98M/R232Q mice. We found the neuromuscular junction (NMJ) endplate size was slightly diminished in

Nmnat2V98M/R232Q mice even as early as 2 months of age (Figure 4A,
yellow arrows). The NMJ postsynaptic volume continued to progressively diminish over time, consistent with loss of presynaptic
inputs (Figure 4, A and B). Apposition of the presynaptic nerve terminal and the postsynaptic endplate is a major determinant of NMJ
functionality. Indeed, the ratio of overlap between presynaptic vesicles and the underlying acetylcholine receptor clusters (NMJ occupancy) was reduced in the NMJs of 2-month-old Nmnat2V98M/R232Q
mice and continued to decrease over time (Figure 4, A and C).
In addition, endplate complexity was decreased in 12 month old
Nmnat2V98M/R232Q mice, whereas the prototypical pretzel-like end-
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Figure 4. Nmnat2 variants cause NMJ dysfunction and muscle wasting in mice. (A) Representative images of 2- and-12 month-old mouse NMJs stained for
synaptic vesicle 2/neurofilament (green) and bungarotoxin (red). Scale bars: 20 μm. (B) Synapse volume quantification for NMJs from WT (n = 44–62 synapses) and Nmnat2V98M/R232Q (V/R; n = 48–63 synapses) mice. (C) NMJ occupancy quantification for NMJs from WT (n = 25–43 synapses) and Nmnat2V98M/R232Q (n
= 25–55 synapses) mice at 2, 6, and 12 months. (D) Average tibialis anterior weight/body weight for WT and Nmnat2V98M/R232Q mice at 2, 6, and 9–12 months
(n = 3–11 mice per age cohort, per genotype). (E) Representative images of laminin immunofluorescence in Nmnat2V98M/R232Q mouse tibialis anterior muscles
at 2, 6, and 9–12 months. WT mouse tibialis anterior muscle at 12 months shown for comparison. The apparent fuzziness shown in the representative image
of Nmnat2V98M/R232Q 9–12-month-old mouse muscle was a consistent genotype-dependent finding reflecting diffuse laminin staining. (F) Quantification of
muscle fiber cross-sectional area (n = 3 mice per genotype, per age cohort). Scale bars: 150 μm. All data are presented as mean ± SEM. Statistical significance
determined by Student’s unpaired, 2-tailed t test or 2-way ANOVA with multiple comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001.

plate structure was still observed in 2 month old Nmnat2V98M/R232Q
mice (Figure 4A, yellow arrows). Alterations in endplate size and
complexity suggest repeated episodes of denervation and reinnervation. At steady state, the majority of Nmnat2V98M/R232Q endplates
appeared partially innervated (Figure 4A); however, almost all preterminal motor axons were abnormally thin and smooth (Figure
4A, white arrows), a hallmark of sprouting axons (40). Sprouting is
frequently observed in NMJs of motor neuron disease models and
is evidence of continual axonal degeneration and regeneration (40–
43). Taken together, these data indicate that decreased NMNAT2
activity causes progressive degeneration of terminal axons at the
NMJ, which is consistent with a chronic motor neuropathy.
The patients with compound heterozygous variants in
NMNAT2 have both proximal and distal weakness with predominantly distal muscle atrophy, rendering them wheelchair bound.
6

Loss of nerve terminals at the NMJ results in muscle fiber denervation and eventual muscle atrophy. Nmnat2V98M/R232Q mice exhibited a progressive reduction in hindlimb muscle mass (Figure 4D)
that correlated with decreased fiber cross-sectional area in the
tibialis anterior muscle (Figure 4, E and F). Together, these results
confirm that the decreased activity of the Nmnat2V98M/R232Q mice
leads to axon loss and subsequent muscle denervation and atrophy. Importantly, the Nmnat2V98M/R232Q mouse model recapitulates
chronic motor features of the human syndrome, providing strong
evidence that the NMNAT2 variants are indeed pathogenic.
Neuronal SARM1 is required for Nmnat2V98M/R232Q neuropathy.
SARM1 is a prodegenerative enzyme activated by binding to the
NAD+ precursor NMN at its allosteric site (9). NMNAT2 converts
NMN to NAD+, thereby preventing the buildup of NMN and
its interaction with SARM1. In Nmnat2-KO mice, the increase
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Figure 5. Neuronal SARM1 is required for Nmnat2V98M/R232Q neuropathy. (A) Relative cADPR levels in sciatic nerves of 2-month-old WT (n = 3),
Nmnat2V98M/R232Q (n = 4), and Nmnat2V98M/R232Q; Sarm1-KO (n = 3) mice. Values normalized to WT cADPR levels (set to 1). Statistical significance
determined by a Student’s unpaired t test. (B) Average tibialis anterior weight by body weight for WT, Nmnat2V98M/R232Q, and Nmnat2V98M/R232Q;
Sarm1-KO mice in 2- and 9–12-month-old mice (n = 3–11 mice per age cohort, per genotype). (C) Average time suspended from an inverted screen
(max. 120 seconds) for WT (n = 3–7), Nmnat2V98M/R232Q (n = 3–21), and Nmnat2V98M/R232Q; Sarm1-KO (n = 7–13) mice. (D–F) Representative images of
sciatic (D), femoral (E), and sural (F) nerves in 9–12-month-old Nmnat2V98M/R232Q; Sarm1-KO mice. Scale bars: 50 μm. Percent axonal area/total
nerve area is calculated below each corresponding nerve (n = 3–11 mice per age cohort, per genotype). Statistical significance was determined
by 2-way ANOVA with multiple comparisons. (G) Schematic of AAV-SARM1-DN gene therapy experiment. (H) Percent initial performance on
inverted screen test at 2 months and 6 months for EGFP (control) (n = 6) or SARM1-DN–injected (n = 7) Nmnat2V98M/R232Q mice. (I) Quantification
of GFP fluorescence in the spinal cord of SARM1-DN injected Nmnat2V98M/R232Q mice, stratified by rescue (Rescue was determined as an endpoint
performance (6m) greater than the mean control arm endpoint performance.) All data are presented as mean ± SEM. Statistical significance
within treatment group was determined by a Student’s paired, 2-tailed t test. Statistical significance between treatment groups determined by a
Student’s unpaired, 2-tailed t test.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
J Clin Invest. 2022;132(23):e159800 https://doi.org/10.1172/JCI159800
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Figure 6. Activated macrophages accumulate in the peripheral nervous system of Nmnat2V98M/R232Q mice. (A–E) Representative images of CD68 immunofluorescence and DAPI signal in the spinal cord, original magnification, ×10 (A and B) and sciatic nerves, original magnification, ×20 (C–E) of 2-monthold WT, Nmnat2V98M/R232Q, and Nmnat2V98M/R232Q; Sarm1-KO mice. (F) Representative scatter plots and quantification of fluorescence-activated cell sorting
of total sciatic nerve macrophages (CD64+ CD11b+) in 2-month-old WT (n = 3), Nmnat2V98M/R232Q (n = 3), and Nmnat2V98M/R232Q; Sarm1-KO (n = 3) mice. (G)
Relative cADPR levels in sural and femoral nerves of 4-month-old WT (n = 5), Nmnat2V98M/R232Q (n = 4), and Nmnat2V98M/R232Q; Sarm1-KO (n = 5) mice. Values
normalized to WT cADPR levels (set to 1). (H) Relative levels of CD68+ macrophages in sural and femoral nerves of 4-month-old WT (n = 4), Nmnat2V98M/
R232Q
(n = 3-4) and Nmnat2V98M/R232Q; Sarm1-KO (n = 2-3) mice. Values normalized to WT CD68+ macrophage levels (set to 1). All data are presented as mean ±
SEM. Statistical significance determined by 1-way ANOVA with multiple comparisons, ****P < 0.0001.

in NMN leads to axon projection abnormalities and perinatal
death; however, Nmnat2/Sarm1 double-KO mice are viable and
completely resistant to injury-induced programmed axon degeneration (13). To determine whether SARM1 is activated in Nmnat2V98M/R232Q mice, we first monitored nerve levels of cyclic ADP
ribose (cADPR), a specific biomarker of SARM1 NAD+ hydrolase
8

activity (44). Metabolites were isolated from the sciatic nerve
of 2-month-old Nmnat2V98M/R232Q mice and analyzed by liquid
chromatography with tandem mass spectrometry (LC-MS/MS).
We found that cADPR levels were elevated 8-fold compared
with Nmnat2WT, and that this increase was fully SARM1-dependent (Figure 5A). This demonstrated that SARM1 was activated

J Clin Invest. 2022;132(23):e159800 https://doi.org/10.1172/JCI159800

The Journal of Clinical Investigation  

J Clin Invest. 2022;132(23):e159800 https://doi.org/10.1172/JCI159800

RESEARCH ARTICLE

9

RESEARCH ARTICLE

The Journal of Clinical Investigation  

Figure 7. Macrophages are activated throughout disease and express
markers of M1 and M2 polarization. (A) Sample correlation plot showing
global transcriptomic analysis and hierarchical clustering of sciatic nerve
macrophages from WT and Nmnat2V98M/R232Q mice. Each box represents 1
replicate (n = 3). (B) Volcano plot of significant codifferentially expressed
(DE) genes in sciatic nerves of 2 month and 6 month Nmnat2V98M/R232Q
old mice, highlighting activated macrophage markers (red) and repair SC
signatures (purple). (C) GO analysis of genes enriched in sciatic nerves of
6-month-old Nmnat2V98M/R232Q mice. (D–G) Representative images of CD68,
Arg1, and iNOS immunofluorescence in the sciatic nerves of (D) WT mice 3
days after nerve crush (3dpNC) and (E–G) Nmnat2V98M/R232Q sciatic nerves at
2, 6, and 12 months. Scale bars: 50 μm, 15 μm (insets). Yellow arrows indicate Arg1/CD68 colocalization and blue arrows represent Arg1/iNOS/CD68
colocalization. Inset depicts a magnified image of a polarized macrophage.
All data are presented as mean ± SEM. Statistical significance determined
by 1-way ANOVA with multiple comparisons.

even at this early stage of the disease and suggested that cADPR is likely an useful biomarker for syndromes involving chronic
SARM1 activation.
Next, we mated the Nmnat2V98M/R232Q mutant mice with Sarm1KO mice to generate Nmnat2V98M/R232Q; Sarm1–KO mice. In contrast
with Nmnat2V98M/R232Q (Sarm1 WT) mice, Nmnat2V98M/R232Q; Sarm1–
KO mice did not develop motor function deficits (Figure 5, B and
C). We also performed morphological analysis of the sural, femoral, and sciatic nerves of Nmnat2V98M/R232Q and Nmnat2V98M/R232Q;
Sarm1-KO mice. As with the functional studies, loss of Sarm1
prevented axon degeneration even in the oldest Nmnat2V98M/R232Q
mice (Figure 3A and Figure 5, D–F). These results confirm that the
phenotypes associated with these pathogenic NMNAT2 variants
are SARM1-dependent and do not arise secondary to neomorphic
functions of the mutant NMNAT2 enzymes. These results suggest that Nmnat2V98M/R232Q mice will be useful for testing treatment
strategies for progressive neurodegenerative disease involving
chronic SARM1 activation.
The development of small molecule and gene therapy SARM1
inhibitors is underway (45, 46); indeed, we previously showed that
adeno-associated virus–mediated (AAV-mediated), neuron-specific expression of a potent SARM1 dominant-negative (SARM1-DN)
variant blocks pathologic axon degeneration in models of acute
nerve injury (45, 47). With the discovery that the Nmnat2V98M/R232Q
motor neuropathy is SARM1-dependent, we next tested whether
this SARM1 gene therapy approach could similarly block disease in
these mice. One-month-old Nmnat2V98M/R232Q mice received intrathecal injections of AAV virions (6 × 1011) expressing SARM1-DNEGFP or EGFP alone (control) under control of a neuron-specific
synapsin promoter (Figure 5G). We assayed inverted screen performance at 2 months and 6 months for both groups and determined
therapeutic efficacy by comparing 6-month to 2-month performance for each mouse. Nmnat2V98M/R232Q mice injected with EGFP
alone displayed an approximately 73% decline in strength by 6
months of age (P < 0.0001) (Figure 5H). In contrast, Nmnat2V98M/R232Q
mice injected with SARM1-DN exhibited a 39% decline (NS, P >
0.05) at 6 months of age (Figure 5H). Importantly, the SARM1-DN
rescue of strength defects was dependent on the extent of viral
infection and transgene expression in the spinal cord, i.e., higher
expression correlated with higher endpoint performance (Figure
5I). These results demonstrated that neuron-specific expression of
10

SARM1-DN potently protects Nmnat2V98M/R232Q mice from developing motor deficits and that neuron-autonomous SARM1 activity is
pathogenic in Nmnat2V98M/R232Q mice.
Macrophages orchestrate Nmnat2V98M/R232Q neuropathy. After acute
nerve injury, macrophages infiltrate the lesion and phagocytose axonal and myelin debris, clearing the injury site and promoting axonal regeneration (26–28). In models of chronic neurodegenerative
disease, macrophages and their CNS counterpart, microglia, play
complex immunomodulatory roles as both proinflammatory and
antiinflammatory mediators (34, 35, 48–54). We immunostained
central (spinal cord) and peripheral (sciatic nerve) nervous tissue
with antibodies against the activated macrophage marker CD68
(55). There were few CD68+ cells in central and peripheral tissues of
Nmnat2WT mice (Figure 6, A and C). In contrast, in sciatic nerves of
2-month-old Nmnat2V98M/R232Q mice, CD68+ activated macrophages
(Figure 6E) were abundant, concomitant with a trend toward elevated total (CD64+CD11b+) nerve macrophages (Figure 6F). In contrast, Nmnat2V98M/R232Q mice lacking SARM1 at the same age (Figure
6D) had significantly fewer CD68+ macrophages, and the number
of CD64+CD11b+ macrophages in these animals was similar to the
number seen in Nmnat2WT mice (Figure 6F). CD68+ macrophages
were not detected in the spinal cords of Nmnat2V98M/R232Q mice (Figure 6B), consistent with the predominantly peripheral nervous system defects seen in the patients.
The mixed sensory/motor sciatic nerve and motor-predominant
femoral nerve were both preferentially affected in Nmnat2V98M/R232Q
mice, while the sensory-predominant sural nerve was spared. Thus,
we questioned whether differences in SARM1 activation between
motor and sensory nerves could underlie their differential susceptibility to axon loss or macrophage activation. We first measured
cADPR levels in the femoral and sural nerves of the Nmnat2V98M/R232Q
mice. We found that both nerves exhibited robust SARM1 activation
(Figure 6G). Next, we asked whether SARM1 activation was sufficient to induce macrophage activation in both nerves, akin to what
we observed in the sciatic nerve. Femoral nerves of Nmnat2V98M/R232Q
mice had elevated numbers of activated CD68+ macrophages compared with the nerves of Nmnat2WT and Nmnat2V98M/R232Q ; Sarm1-KO
mice (Figure 6H); in contrast, the sural nerves of Nmnat2V98M/R232Q ,
Nmnat2WT, and Nmnat2V98M/R232Q ; Sarm1-KO mice had comparable
levels of CD68+ macrophages (Figure 6H). Since cADPR was elevated in sciatic, femoral, and sural nerves, but macrophage activation
preferentially occurred only in sciatic and femoral nerves, this finding strongly suggested that SARM1 activation was necessary — but
not sufficient — for macrophage activation. In addition to SARM1
activation in motor axons, these additional unknown signals are
required for preferential activation of the macrophage response.
NAD+ biosynthesis plays a role in programming macrophage
immune responses (56); thus, we examined whether intrinsic
defects exist in macrophages of Nmnat2V98M/R232Q mice due to
impaired NMNAT2 activity. However, we found no differences in
either basal or antigen-induced activation between Nmnat2WT and
Nmnat2V98M/R232Q-derived murine peritoneal macrophages (Supplemental Figure 3). This is consistent with findings from studies
examining other disorders that indicate that signals within the
neural microenvironment shape macrophage activation (57–61).
Here, this is demonstrated by increased numbers of activated
macrophages in the sciatic nerves of Nmnat2V98M/R232Q mice.
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Figure 8. Macrophage depletion rescues motor defects and axon loss in Nmnat2V98M/R232Q mice. (A) Schematic of CSF1R antibody-mediated macrophage depletion in young (beginning at 1-month-old) Nmnat2V98M/R232Q mice. (B) Average time suspended from an inverted screen (max. 120 seconds) for IgG control (n = 5) and
CSF1R-treated Nmnat2V98M/R232Q (n = 7) mice. Statistical significance was determined by 2-way ANOVA with multiple comparisons. (C) Representative images of
femoral nerve from IgG (control) (n = 5), CSF1R (n = 3), or Sarm1-KO Nmnat2V98M/R232Q (n = 4) mice at 4 months. Scale bars: 150 μm. Percent axonal area/total nerve
area for femoral nerve calculated to the right. (D) Schematic of CSF1R antibody-mediated macrophage depletion in aged (beginning at 4-month-old Nmnat2V98M/
R232Q
mice. (E) Change in inverted screen time (s) from pre-treatment (4 months) measured at 5, 6, and months, comparing CSF1R treatment (n = 7) and IgG (control)
(n = 5). Statistical significance was determined by 2-way ANOVA with multiple comparisons. (F) CMAP amplitude (ankle) of Nmnat2V98M/R232Q mice before and after
1 month of CSF1R treatment (n = 7) or IgG treatment (n = 5). (G) Percent axonal area/total nerve area for femoral nerve and sciatic nerve calculated at 7 months (3
months of macrophage depletion (n = 6) or treatment with isotype control IgG (n = 6). All data are presented as mean ± SEM. Statistical significance determined by
Student’s unpaired t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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We performed bulk RNA-Seq on the sciatic nerves of Nmnat2V98M/R232Q and Nmnat2WT mice at early and late disease stages
to capture dynamic changes in the glial and immune cell milieu
(Figure 7A). Global transcriptomic analysis revealed similarities
within the nerves of Nmnat2V98M/R232Q mice at both 2 months and 6
months, which clustered more closely to each other than to nerves
of Nmnat2WT mice. Closer inspection revealed sets of activated
macrophage signatures (57) — including Cd68, Trem2, Apoe, Lrg1,
and Ccl2 — upregulated in the sciatic nerves of both 2-month-old
and 6-month-old Nmnat2V98M/R232Q mice (Figure 7B), consistent
with our observations of CD68+ nerve-associated macrophages
in Nmnat2V98M/R232Q mice. Repair SC markers (62–64) such as Fgf5,
Shh, Ngfr, and Olig1 were also upregulated, suggesting a dedifferentiation program of myelinating SCs. Gene ontology (GO) analysis showed significant enrichment of genes related to the immune
response, inflammation, and phagocytosis in both 2-month-old
and 6-month-old Nmnat2V98M/R232Q mice (Figure 7C and Supplemental Tables 1 and 2). Altogether, these data demonstrate chronic
activation of peripheral nervous system macrophages and an ongoing SC repair program in this mouse model.
Increased numbers of activated macrophages in the nerves
of the Nmnat2V98M/R232Q mice raised the question of whether they
were playing a beneficial or destructive role in the disorder. Classically, macrophages are categorized into 2 opposite extremes:
proinflammatory (M1) or antiinflammatory (M2) (65), although
intermediate, overlapping states are now recognized (66). Indeed,
these states may influence the role macrophages play in disease
development. M1 activation is canonically associated with expression of inducible nitric oxide synthase (iNOS), while M2 activation
is associated with expression of arginase-1 (Arg1) (67). To investigate the activation state of macrophages in the Nmnat2V98M/R232Q
neuropathy, we profiled expression of both iNOS and Arg1 in activated macrophages throughout disease. We found that all activated macrophages (CD68+) coexpressed Arg1 at all examined ages
(Figure 7, E–G, yellow arrow), while expression of iNOS was more
dynamic, with Arg1 and iNOS coexpression (Figure 7, E–G, blue
arrow) in 0%, 34.16% ± 2.204 (n = 3, P < 0.0001), and 12.71% ±
3.776 (n = 3, P = 0.0039) of macrophages at 2, 6, and 12 months
of age, respectively. This noncanonical activation state was also
observed in the sciatic nerves of Nmnat2WT mice 3 days after nerve
crush (Figure 7D, blue arrow), and has been similarly described
in models of acute brain injury (68–70). Concomitant expression
of both polarization signatures suggests that macrophages may
respond to both proinflammatory and antiinflammatory signals
within the nerve microenvironment and that macrophage biology
in this system is more complex than a simple binary phenotype.
Next, we employed a macrophage depletion strategy using
colony stimulating factor 1 receptor (CSF1R) blockade (71, 72) to
directly evaluate the function of macrophages in Nmnat2V98M/R232Q
mice. The mice were treated with CSF1R monoclonal antibody
or the isotype control antibody IgG every 3 weeks beginning at 1
month of age and were assessed using motor function tests at 2, 3,
and 4 months of age (Figure 8A). The efficacy of the macrophage
depletion treatment was confirmed by immunostaining for the
pan-macrophage marker Iba1 alongside CD68 in sciatic nerves
(Supplemental Figure 4, A–C). Given the preponderance of Arg1+
activated nerve macrophages, i.e., the canonical antiinflammatory
12

macrophage phenotype, we predicted that macrophage depletion
would worsen the neuropathy of Nmnat2V98M/R232Q mice. Remarkably, however, macrophage depletion completely blocked the
development of muscle strength defects for the duration of the
experiment. In contrast, Nmnat2V98M/R232Q mice treated with IgG
continued to exhibit poor motor function (Figure 8B). Morphological examination of the femoral — predominantly motor — nerve
showed that macrophage depletion significantly rescued axon
loss in the nerve (Figure 8C), consistent with its ability to prevent
motor function deficits. Together, these data show that macrophages promote axon degeneration that leads to motor function
deficits in this neuropathic mouse model.
Given our finding that macrophages contribute to axonal dysfunction early in the disease, we next tested whether macrophage
depletion would be therapeutic after the initiation of symptoms.
By 4 months of age, Nmnat2V98M/R232Q mice exhibited profound
pathological and functional motor disease (Figure 8, B and C).
Thus, we administered the CSF1R monoclonal antibody (or control IgG) to 4-month-old Nmnat2V98M/R232Q mice to test whether
macrophage depletion could halt or reverse disease progression
(Figure 8D). One month after antibody treatment, the previously
symptomatic mice demonstrated a significant increase in inverted screen performance, demonstrating a profound recovery of
muscle strength (Figure 8E). Improvement in overall strength was
accompanied by improved distal CMAP responses (Figure 8F).
Such a treatment response indicated that endogenous reparative
processes occurred after macrophage depletion to promote functional recovery. Indeed, in nerve and NMJ pathological studies, we
detected ongoing axon degeneration and regeneration processes
in Nmnat2V98M/R232Q mice at steady state. Rescue of muscle strength
persisted until the mice were 7 months old, at which point muscle
strength was maintained at pretreatment levels. Endpoint examination of macrophage-depleted peripheral nerves revealed significant rescue of sciatic and femoral nerve axon loss (Figure 8G).
CSF1R inhibition can alter macrophage polarization (73); thus,
we examined whether the remaining population of macrophages
after depletion exhibited altered activation or polarization phenotypes. We found a modest trend toward reduced activation of the
remaining nerve macrophages in Nmnat2V98M/R232Q mice (Supplemental Figure 4D). However, we found no evidence of alterations to their
polarization phenotype compared with IgG treated Nmnat2V98M/R232Q
mice (Supplemental Figure 4, E and F, yellow and blue arrows), indicating that the constellation of polarization signals within the nerve
microenvironment or within the remaining macrophages themselves
was not altered by macrophage depletion.
Altogether, these data support a model wherein macrophage
depletion blocks axon degeneration, tipping the balance toward
innate axon reparative processes and, thus, symptom reversal.
Importantly, the finding that macrophage depletion reversed
both behavioral and electrophysiologic defects underscored the
potential of acute macrophage-targeted therapies in chronic neurologic diseases.

Discussion

Genetic deletion of NMNAT2 is perinatal lethal; however, when
combined with SARM1 deletion, mice are viable and resistant to
injury-induced axon degeneration (13). Recent advances in our
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understanding of the mechanisms underlying axon degeneration
directly connected NMNAT2 loss to SARM1 activation through
dynamic changes in the NMN-to-NAD+ ratio (9). These studies
suggest that defects in NMNAT2 could predispose an individual to develop neurodegenerative disease; however, there is little
direct evidence connecting mutations in the genes involved in axon
degeneration to human neurological disease. Here, we examined 2
brothers with severe neuropathy associated with NMNAT2 mutations. This neuropathy initially presented with sensory and motor
symptoms and progressed to be a predominantly motor neuropathy
with severe muscle wasting. To study the molecular mechanism
underlying this syndrome, we developed a mouse model harboring
the Nmnat2V98M/R232Q mutations. This mutant mouse recapitulated
the cardinal motor features of the human syndrome. We found that
NMNAT2 enzymatic deficiency lead to chronic SARM1 activation
that, in turn, lead to non-cell-autonomous macrophage activation
and axon loss. Our study has several important implications. First,
the creation of our mouse model enables longitudinal examination
of a SARMopathy and provides a powerful platform for testing novel
axo-protective therapeutics in disorders of chronic SARM1 activation. Second, we found that a major prodegenerative role of SARM1
involved the activation of macrophages in parallel with its canonical
cell-autonomous destructive functions. Finally, the identification of
macrophages as key drivers of neuropathology suggested that macrophage depletion therapy could be efficacious in other diseases
involving SARM1-mediated axon degeneration.
While axon degeneration is classically thought of as a programmed injury response to acutely damaged axons, there is
growing evidence that this program is aberrantly activated in progressive neurodegenerative disease. Despite the abundance of
acute injury models involving SARM1 activation, a chronic model
that is more akin to human progressive neurodegenerative disorders is unavailable. Such a model is necessary for testing therapeutics under conditions of subacute SARM1 activation, which
our work now shows involves previously unappreciated complex
biological mechanisms. We found that SARM1 was activated at an
early age in Nmnat2V98M/R232Q mice and that the disease is indeed
fully SARM1-dependent. Moreover, this suggested that SARM1
activation and, thus, axon loss does not occur as an all-or-nothing event in chronic neurodegenerative disorders. Rather, this
disorder appeared to be characterized by persistent SARM1 activity, suggesting that therapeutic intervention could be efficacious
across a broad disease timeline in such disorders.
Patients with compound heterozygous variants NMNAT2V98M
and NMNAT2R232Q develop a unique sensorimotor neuropathy
involving both chronic and episodic symptomology. Chronic features of the disease are motor predominant, while episodic features
involve prominent sensory and motor components. The patients
typically develop acute episodes after infection, whereas the
Nmnat2V98M/R232Q mouse model unsurprisingly shows no evidence of
episodic disease features, likely due to housing in a pathogen-free
environment. The mouse model does recapitulate cardinal features
of the chronic symptomatology, including a motor axonal neuropathy, distal muscle wasting and weakness, and a progressive disease
course. Unlike the patients, the Nmnat2V98M/R232Q mouse model had
no evidence of a neuropathic pain phenotype, suggesting either
species-dependent differences or that the episodic attacks seen in

the patients but not in the mice contribute to the neuropathic symptoms. Interestingly, 2 sisters homozygous for a different NMNAT2
variant (T94M) — one that largely retains enzymatic activity — also
display peripheral neuropathy, albeit significantly milder than the
patients described in this study (27).
Through this study, in both patients as well as the mice, it
appeared that the peripheral nervous system was preferentially affected by NMNAT2 dysfunction, likely due to the longer
length of peripheral axons. NMNAT2 has a very short half life
and is transported from the soma to the axon, thus, distal regions
are likely to be more sensitive to changes in NMNAT2 activity. Hence, the peripheral defects we observed are likely a result
of axon-length-dependent SARM1 activation. The NMNAT2/
SARM1 axon degeneration pathway functions in both sensory
and motor neurons; yet, curiously, Nmnat2V98M/R232Q mice primarily develop a motor peripheral neuropathy. This is consistent with
a Nmnat2 hypomorphic allele that also displays peripheral motor
defects (74). In contrast, in the Nmnat2-null mice, SARM1 drives
loss of both sensory and motor nerves (75), begging the question
as to why motor neurons are preferentially affected in Nmnat2V98M/R232Q mice. Potentially, motor neurons are more vulnerable
to chronic, low-level SARM1 activation, either due to a decreased
tolerance for NAD+ loss or to increased susceptibility to macrophage-induced degeneration. In support of this hypothesis, germline constitutively active SARM1 variants are enriched in patients
with ALS (23, 24), suggesting that SARM1 activation results primarily in motor loss in vivo. Moreover, while both Nmnat2V98M/R232Q
sural and femoral nerves exhibited robust SARM1 activation, there
was no evidence of macrophage activation in the sural nerve.
Additional study of differential motor versus sensory axon susceptibility is required to answer these fundamental questions.
Studies of many common chronic neurodegenerative disorders have implicated the immune system as a key driver of
disease, and activated macrophages are major contributors to
tissue damage (76). Similar to CD68+ microglia observed in
patients with Alzheimer’s disease (77) and LPS-induced central
neuroinflammation (78), CD68+ macrophages are abundant in
the peripheral nervous system of Nmnat2V98M/R232Q mice, indicating that CD68+ macrophages are activated. Importantly, macrophage activation begins early in the disease, before significant
axon loss has occurred, and in response to unknown signals
within the neural microenvironment. We found that treating
Nmnat2V98M/R232Q mice with a neuron-specific AAV expressing a
SARM1-DN molecule to prevent SARM1 activation specifically in neurons prevents motor dysfunction. Altogether, these
data argue that macrophage activation occurs via an extrinsic
SARM1-dependent signal rather than a macrophage-autonomous program in this model.
An unexpected finding from our study was that immunodepletion of macrophages both prevents and reverses Nmnat2-associated motor defects. Indeed, macrophage depletion in young mice
blocked the development of a motor neuropathy in Nmnat2V98M/R232Q
mice. Moreover, recovery of overall strength and improved nerve
electrophysiology in older, macrophage-depleted Nmnat2V98M/R232Q
mice demonstrated that axon dysfunction could be reversed in
the presence of persistent SARM1 activation; however, this effect
lessens as the disease progresses. While all recent mechanistic
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progress on SARM1 has defined it as the central driver of a cell-autonomous degenerative program via its NAD+ hydrolase activity (4,
5), our data support what we believe to be a new paradigm wherein
chronic axonal SARM1 activation can also orchestrate non-cell-autonomous axon degeneration. Importantly, these findings indicate
that macrophages are downstream effectors of SARM1 activation
in vivo, placing SARM1 at the nexus between neuroinflammation
and neurodegeneration.
Examination of the macrophage polarization states in
Nmnat2V98M/R232Q mice revealed a bias toward expression of Arg1,
a canonical M2 signature gene. Contrary to the central tenets of
M1/M2 polarization phenotypes, depletion of these Arg1+ macrophages in presymptomatic mice blocked rather than worsened the Nmnat2V98M/R232Q nerve pathology. We acknowledge
that our work is by no means exhaustive of all genes involved in
M1/M2 polarization; however, we suggest that binary polarization terms may be less meaningful in our system for describing
macrophage phenotypes. Indeed, other groups have uncovered
canonical markers of M1/M2 states coexpressed in individual
cells after acute brain injury (68–70) and found that high Arg1
expression by microglia drives neuropathology in an AD model
via immune suppression (79), underscoring the pitfalls of the
existing macrophage/microglia classification framework in the
nervous system.
So, how do macrophages induce axonal dysfunction in this syndrome? Evidence from studies of disease-associated microglia has
established phagocytosis of live neurons, termed phagoptosis, as
contributing to CNS inflammation and neurodegeneration (80). In
the present study, the absence of motor defects or axon loss after
3 months of macrophage depletion in young Nmnat2V98M/R232Q mice
suggests that macrophages target axons that are either functional at
baseline or can recover (i.e., stressed-but-viable) in the absence of
macrophage attack. Pathologic evidence in the nerves and NMJs of
Nmnat2V98M/R232Q mice points to a continual process of axon degeneration and regeneration, as has been observed in other chronic
neurodegenerative diseases (81, 82). Moreover, reversal of motor
deficits with macrophage depletion after disease onset suggest that
there was effective and ongoing regeneration once axon degeneration was blocked.
Our study raises fundamental questions regarding the molecular crosstalk between the SARM1 degeneration pathway and the
immune system. For example, what is the macrophage activation
signal? Our data demonstrate that SARM1 activation was necessary but not sufficient for macrophage activation, as SARM1
activation in motor but not sensory axons induced macrophage
activation. SARM1 activity drove calcium influx in damaged
axons, which was followed by exposure of the phagocytic “eatme” signal phosphatidylserine (PS) on the extracellular leaflet of
the plasma membrane, and later, frank axon degeneration (83).
SARM1 is required for PS exposure in response to axotomy- and
vincristine-induced axon degeneration (84), and PS exposure
is a driver of axon phagocytosis (85). These data suggest that
phagocytic recognition of exposed PS may, indeed, be the primary mechanism for clearance of metabolically stressed-but-viable axons in vivo and that cell-autonomous axon degeneration
caused by SARM1-mediated NAD+ depletion may only occur
later as a last resort for terminally dysfunctional axons, akin to
14

what has been observed in Drosophila (86). Further studies will
be required to address the macrophage activation signal and its
motor selectivity in this model.
Our data support a model wherein loss of vulnerable axons
is accelerated by their engulfment by activated macrophages.
Therefore, we hypothesize that macrophages are key initiators
of disease in this model of a SARM1-dependent motor neuropathy, akin to their previously described roles in other common
neurodegenerative diseases including MS, AD, Parkinson’s disease, and ALS (87). We predict that SARM1 activation eventually leads to neuron-autonomous axon degeneration that is not
prevented by immunomodulatory therapy. Indeed, this may
explain the waning rescue offered by macrophage depletion in
older Nmnat2V98M/R232Q mice. The findings herein demonstrate an
acute benefit for use of currently available macrophage-targeted therapy. Given that Sarm1-KO and SARM1-DN gene therapy
both confer robust protection in this model, use of future small
molecule and gene therapy SARM1 inhibitors in combination
with immune targeted therapies could be optimal for long-term
therapy of chronic SARMopathies.
While this study focuses on a very rare genetic cause of neuropathy, SARM1 has been implicated in an expanding number of
other, more common neurodegenerative diseases including traumatic brain injury, diabetic neuropathy, chemotherapy-induced
neuropathy, glaucoma, and retinal degeneration(3). Importantly,
we and others have identified rare hypermorphic human SARM1
alleles in patients with ALS (23, 24). Our work suggests that,
in addition to SARM1 inhibition, these patients are also candidates for macrophage-targeted therapies. In summary, our study
implies the existence of a SARM1-dependent, non-cell-autonomous pathway for axonal dysfunction that is amenable to targeted immunomodulatory therapy and presents a mechanistically
defined mouse model of a pure SARMopathy in which to test
such treatment strategies.

Methods
Whole-exome sequencing
Whole-exome sequencing and sequence analysis were performed
by the Division of Genomic Diagnostics Genetic Counseling Core
at Children’s Hospital of Philadelphia. Genomic DNA was extracted from peripheral blood following standard DNA extraction protocols. Targeted exons were captured with the Agilent SureSelect
XT Clinical Research Exome kit per manufacturer’s protocol,
sequenced on the Illumina HiSeq 2000 or 2500 platform with
100bp paired-end reads, and sequencing variants were identified using an in-house, custom-built bioinformatics pipeline as
described previously (88). Mapping and analysis were based on
the human genome build UCSC hg19 reference sequence. Single nucleotide variants, small deletions, and small insertions
were detected. Suspected pathogenic variants were confirmed by
Sanger sequencing.
Constructs
The Takara HD InFusion Cloning Kit was used to introduce R232Q
and V98M mutations into the complete open reading frame of the
canonical 307 aa human NMNAT2 allele. This was fused to a FLAG
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tag followed by a 10 aa linker sequence and C-terminal 2 X Strep Tag
II cloned into the lentiviral vector FCIV.

HEK293T transfection
HEK293T cells (ATCC) were cultured in DMEM with 2mM glutamine
(Thermo Fisher Scientific) and 1% penicillin/streptomycin (Thermo
Fisher Scientific), and 10% FBS. Cells were plated in 12-well format
to reach 25%–35% confluence before transfection with polyethyleneimine (PEI, 1mg/mL, pH 7.0) using a ratio of 3:1 (PEI:plasmid DNA).
200ng StrepTag-NMNAT2-Flag expression vectors (reference allele,
V98M, and R232Q) were transfected per well. 1mg/mL Cycloheximide (Sigma-Aldrich) was used to block protein synthesis 24 hours after
transfection. Cells from one well per time point after treatment were
suspended in 100μL of 100mM Tris-Cl (Corning), pH 8.0, and 150mM
NaCl with Protease Inhibitor Cocktail (Buffer 1; Pierce), sonicated to
fragment the genomic DNA, then mixed with 30μL of 4xNuPage LDS
sample buffer (Invitrogen). After heating to 90°C for 5 minutes, equal
amounts of each lysate were used for Western blotting.
Western Blot
Cell lysates were resolved using SDS-PAGE on 4%–12% Bis-Tris Plus
gel (Invitrogen), transferred to PVDF membrane (Invitrogen), and followed by immunoblotting for Flag (1:1,000 Mouse anti-flag M2 monoclonal, Sigma-Aldrich, F3165 ) and β-tubulin (1:1,000 anti-β-tubulin,
DSHB, clone E7), and visualization by standard chemiluminescence.
NMNAT recombinant protein expression and purification
Constructs described above, the human reference NMNAT2 allele, and
NMNAT2 variants V98M or R232Q, were transfected into HEK293T
cells in a 150 mm diameter cell culture dish. Cells were harvested 48
hours after transfection and resuspended in Buffer 1 and placed on ice
during lysis by sonication. After centrifugation, the supernatant was
mixed with PureCube HiCap Streptactin MagBeads (Cube Biotech)
for 1 hour. Proteins were eluted with Buffer 1 plus 5 mM desthiobiotin (Sigma-Aldrich) and stored at –80°C. Concentrations were determined by the Bio-Rad protein assay. Protein purity was assessed by
4%–12% SDS-PAGE and Coomassie staining.
NMNAT activity assay
NMNAT activity was defined as 1 mmol NAD+ generated per minute per
mg of protein. The reaction was initiated by mixing purified NMNAT2
protein at 1–2 mg/mL with 100 mM ATP and 100 mM NMN in 10 mM
HEPES, pH 7.4, and 5 mM MgCl2 at 37°C. The reactions were stopped
by removing 100 μL from the reaction and mixing it with 100 μL 0.5 M
perchloric acid (HClO4) on ice for 10 minutes. After centrifugation, the
supernatant was mixed with 11 μL 3 M K2CO3 for neutralization. Samples were placed on ice for another 10 minutes and centrifuged. 45 μL of
supernatant containing extracted metabolites was mixed with 5 μL 0.5 M
potassium phosphate buffer and quantified by HPLC (Nexera X2) on a
Kinetex column (100 × 3 mm, 2.6 μm; Phenomenex). An NAD+ standard
(Sigma-Aldrich) was used to generate a standard curve for the quantification of NAD+ in the extraction. NAD+ production at 10 minutes, which is
within the steady state, was used to calculate NMNAT activity.
Generation of Nmnat2V98M/R232Q compound heterozygous mice
All animal experiments were performed under the direction of institutional animal study guidelines at Washington University (St. Louis,

Missouri, USA). To generate Nmnat2V98M/R232Q mice via CRISPR/Cas9,
guide RNAs were designed by the Washington University School of
Medicine Genome Engineering & iPSC Center, and individually created gRNAs were microinjected into B6CBAF2/J pronuclei along with
Cas9 protein and donor DNA oligonucleotides engineered to introduce the desired mutations by homology-directed repair. Properly
mutated transgenic mice with individual mutations were confirmed
by sequencing. Founder mice were initially mated to C57BL/6J mice
and heterozygotes for each allele were subsequently mated together
to generate compound heterozygotes. Compound heterozygotes were
initially sequenced to confirm they carried both mutations, 1 from each
parental chromosome (Supplemental files 1 and 2). Subsequent genotyping was performed by genomic PCR using the following primers:
Nmnat2 V98M (CCTATGCAAGATTCCTCTCAGT, ATCGTCGTGGTACCCCAA), Nmnat2 R232Q (ACCATGATGTTGTTCTGGAAAC,
GGTGCTCCAACATACTGCAT), and Nmnat2 WT (ACCATGATGTTGTTCTGGAAAC, GTGCTCCAACACACTGCAG). Unless stated
otherwise, both female and male mice were used for all experiments.
Sarm1-KO mice were a gift from Marco Colonna in the Department of
Pathology and Immunology, Washington University School of Medicine. Sarm1-KO mice were crossed to Nmnat2V98M/R232Q mice to produce
Nmnat2V98M/R232Q; Sarm1-KO mice.

Nerve structural analysis
Sciatic, sural, and femoral nerves were processed as previously
described (15, 89). Sciatic nerves were embedded so that the most
distal portion was sectioned. For the light microscope analysis of
400–600 nm, semithin sections were cut using Leica EM UC7
Ultramicrotome and placed onto microscopy slides. Toluidine blue
staining and quantification were performed as previously described
(89). All quantifications were performed by an investigator blinded
to genotype.
Tissue immunohistochemistry
Nervous tissue. Six μm–thick sections of sciatic nerves and 20 μm–thick
sections of spinal cord were prepared on a cryostat (Leica CM1860),
mounted onto slides, and processed as previously described (15)
using the following antibodies:(a) for activated macrophages, primary
Ab CD68 (1:100, Bio-Rad, MCA1957GA) and secondary Ab anti-rat
Cy3 (1:500, Jackson Immunoresearch, 112-165-143); (b) for total macrophages, primary Ab Iba-1 (1:500, Wako Chemicals, 019-19741) and
secondary Ab anti-rabbit Alexa Fluor 488 (1:500, Invitrogen, A11034);
(c) for M1 macrophages, primary Ab iNOS (1:50, Proteintech, 189851-AP) and secondary Ab anti-rabbit Alexa Fluor 647 (1:500, Invitrogen, A27040); (d) for M2 macrophages, primary Ab Arg1 (1:400,
Proteintech, 66129-1-IG) and secondary Ab anti-mouse IgG1 (1:400,
Invitrogen, A-21121); (e) for GFP fluorescence, rabbit anti-GFP Alexa
Fluor 488 (1:200, Invitrogen, A-21311); (f) for Motor neuron cell bodies,
primary Ab ChAT (1:100, Sigma-Aldrich, AB144P) and secondary Ab
anti-rat Cy3 (1:250, Jackson Immunoresearch, 112-165-143).
Sciatic nerves were imaged with the Leica DMI 4000B confocal
microscope at ×20 magnification. Spinal cords were imaged using
a scheme covering 100% of the total spinal cord area with image
stitching for quantification. ImageJ was used for quantification of
integrated fluorescence density quantification from 3 independent
sections per mouse. Motor neuron numbers were manually counted
in the ventral horn using ImageJ.
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Tibialis anterior muscle. Ten μm-thick sections of the tibialis
anterior muscle were processed as described (15) and stained with
primary Ab laminin (1:100, Sigma-Aldrich, L9393) and secondary Ab anti-rabbit Cy3 (1:500, Invitrogen, A10520). Muscle fiber
cross-sectional area was calculated by averaging fiber cross-sectional area from ≥ 150 muscle fibers per mouse from 3 independent
magnification ×20 images.

NMJ analysis
NMJ preparation and staining was performed as previously described
(90). To analyze NMJ morphology, z-stack images were obtained.
Maximal intensity projection images were analyzed to determine the
volume of endplates using Imaris software. Fifteen to 20 NMJs were
analyzed per mouse. NMJ occupancy was calculated as a ratio of presynaptic axonal area (SV2/2H3) to postsynaptic area. As the value
approaches 1.0, the motor endplates are fully occupied by axons.
Intraepidermal nerve fiber density quantification
Intraepidermal nerve fiber (IENF) staining and quantification were
performed as previously described (15, 91). Footpads were imaged on a
Leica DMI 4000B confocal microscope. IENF density was quantified
as the number of PGP9.5+ axons that crossed the basement membrane
normalized to the length of the basement membrane. IENF densities
were averaged in 3 separate sections for each animal. Imaging and
analysis were performed by an investigator blinded to genotype.
Tissue metabolite measurements
Nervous tissue metabolites were extracted and measurements were
acquired as previously described (89, 90).
AAV constructs and virus injections
AAV constructs were created as previously described (45). Briefly,
AAV8-hSYN-SARM1-DN-EGFP was generated by the viral vector core
of the Hope Center for Neurological Disorders at Washington University in St. Louis. Under light anesthesia with Avertin, 6 × 1011 viral
genomes were injected intrathecally at L6/S1. Viral expression was
confirmed by detecting EGFP expression via immunohistochemical
analysis of spinal cords.
Nerve electrophysiology
CMAPs were acquired as previously described (92) using a Viking
Quest electromyography device (Nicolet). Supramaximal stimulation was used for CMAPs. Sensory nerve action potentials (SNAPs)
were acquired as previously described (15) using a Viking Quest
electromyography device (Nicolet). Supramaximal stimulation was
used for SNAPs.
Behavioral tests
Tail flick assay. The tail flick assay was performed as previously
described (93). Briefly, mice were restrained horizontally, and the tips
of their tails were submerged in a 55°C water bath. Latency to withdraw from the water bath was measured using a stopwatch. Five trials
were performed and averaged for each mouse.
Inverted screen assay. The inverted screen assay was performed
as previously described with minor modifications (94). Mice were
placed on a wire mesh screen. Latency to fall for each mouse was
recorded, and each mouse underwent 3 trials with 5-minute rest
16

periods. If a mouse did not fall off the mesh screen within 120 seconds, then that time was recorded, and the mouse was taken off
the screen.
Hindlimb grip strength. Hindlimb grip strength was measured
using a computerized grip strength meter. The maximum force of each
measurement was measured and recorded by the grip strength meter.
Each mouse underwent 5 trials. If a mouse could not establish a grip on
the bar, then the value for that trial was recorded as 0.

Flow cytometry
Nerves were collected and kept on ice until dissociation. Nerves were
then minced and incubated with gentle shaking for 20 minutes in digestion media containing 0.3% collagenase IV, 0.04% hyaluronidase, and
0.04% DNase in DMEM at 37°C. Cells were then washed and filtered
through 70 μm strainers. Dead cells were excluded by propidium iodide
(PI). Antibodies to the following proteins were used: CD11b (BioLegend,
clone M1/70), CD45 (Thermo Fisher Scientific, clone 30-F11), and CD64
(BioLegend, clone X54-5/7.1). Cells were analyzed on an LSRII flow
cytometer (BD Biosciences) and analyzed with FlowJo software.
RNA-Seq and analysis
RNA-Seq and analysis was performed as previously described (57,
95). These data have been deposited in the Gene Expression Omnibus
repository under the reference series ID GSE210403.
CSF1R antibody injections
Macrophages were depleted by administering 1.5 mg of anti-mouse
CSF1r (Bio X Cell, clone AFS98) or Rat IgG (Sigma-Aldrich, I4131) via
i.p. injection every 3 weeks for a total of 4 injections.
Macrophage activation assay
Peritoneal macrophages were harvested from individual mice by
peritoneal lavage using ice-cold DMEM containing 1% FBS. Cells
were then transferred into plates and subjected to either PBS or LPS
treatment at a concentration of 10 ng/mL for 4 hours at 37°C.
Statistics
Unless otherwise stated, data are reported as mean ± SEM. Betweengroup comparisons were made with 1-way and 2-way ANOVA with
post hoc Holm-Sidák multiple comparison test or paired and unpaired
2-tailed t tests, as appropriate. 2-sided significance tests were used
throughout and P < 0.05 was considered statistically significant. All statistics were calculated with the aid of GraphPad Prism 9 (https://www.
graphpad.com/scientific-software/prism/) software.
Study approval
Mice were housed and used following institutional animal study guidelines at Washington University in St. Louis. These protocols received
approval from the Washington University IACUC. The patients’ parents
provided written informed consent at Children’s Hospital of Philadelphia while the patients were minors. Once adults, both patients independently provided written informed consent in March 2021.
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